We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.
Most Recent Posts
Yesterday, the latest Congressional Budget Office (CBO) report was released examining projected long-term federal spending, including that of Medicare.
It’s likely many of us have paused to think about what life would have been like in a bygone time and felt thankful for the modern comforts we enjoy, from refrigeration to cell phones. When looking at the progress we’ve made and the comforts we enjoy, medical innovation should be at the top of the list.
This week, we addressed some of the barriers that patients face when it comes to their health and how the biopharmaceutical industry helps individuals get the treatments they need.
A new story from the AP today, “Patient advocates say insurers avoiding the sick,” highlights the growing concern among patients and insurance commissioners about high cost-sharing for medicines in the new health insurance exchanges.
The science of informatics drives innovation that is defining future approaches to information and knowledge management in biomedical research, clinical care, and public health.
A new PhRMA survey found that Americans are paying more attention to their health, and, thanks to the countless resources at our fingertips, information is often just a click away. Easy access to vast amounts of information, however, has led to misconceptions about what is and isn’t healthy. Today, for example, just 33 percent of Americans believe it is very easy to get accurate and complete health care information.
Pharmaceutics is that area of biomedical and pharmaceutical sciences that deals with drug delivery systems, in particular the design and evaluation of contemporary pharmaceutical dosage forms so that they are safe, effective, and reliable.
“Despite rigorous and extensive testing for safety and efficacy, a single piece of widely circulated false information can have lasting impact on the public’s perception on vaccine safety.” This month is National Immunization Awareness Month, and as children go back to school, this comment by Conversations contributor Roberta DeBiasi of the Child
This week we released From Hope to Cures: PhRMA’s Second Annual National Health Survey revealing new data on how Americans view their own health as well as that of the Nation. The survey also reveals three new trends that appear to be evolving under the shifting health care landscape.
How we can further improve patients’ lives? This is a question the biopharmaceutical industry is constantly asking. This week on the Catalyst we noted that one way to achieve this is by supporting ways to ensure patients receive, and benefit from treatments.